NEW YORK (GenomeWeb News) — Tripos today said it plans to sell its Discovery Research business to Provid Pharmaceuticals in a stock sale worth roughly $2 million.

 

That price may change, depending on changes in capital, debts, equipment, and facility values, Tripos said. The deal also hinges on Provid’s ability to secure the necessary financing, the company said.